CAS: 192130-34-0; Tert-Butyl 4-(2-Aminoethyl)Piperazine-1-Carboxylate

相似化合物

934-98-5 1484327-92-5 140447-78-5

上下游产品

CAS号24948-82-1 CHLOROETHYLAMINE | CAS号57260-71-6 1-B°C-哌嗪 | CAS号1108149-22-9 tert-butyl 4-[2... | CAS号227776-28-5 4-[2-(1,3-二氢-1,... | CAS号140-31-8 氨基乙基哌嗪 | CAS号100450-84-8 benzylidene-(2-...

📜Tert-Butyl 4-(2-(Benzylideneamino)Ethyl)Piperazine-1-Carboxylate置于potassium Bisulfate体系中,用 水 用作溶剂,化学反应 3.0H,反应生成4-N-(2-胺乙基)-1-N-Boc-哌啶
参考文献:1,4-取代哌嗪衍生物作为三重再摄取抑制剂的设计与合成
标题:1,4-取代哌嗪衍生物作为三重再摄取抑制剂的设计与合成
摘要:通过对 4 种选定的具有抗抑郁活性的含哌嗪化合物进行片段分析和分子修饰,设计了新型 1,4-取代的哌嗪衍生物 5,A 和 B 系列.我们分别合成了 A 系列的 39 种新类似物和 B 系列的 10 种化合物.使用 Neurotransmitter Transporter Uptake Assay Kit 进行针对 Da,Ne 和 5-羟色胺神经递质摄取抑制的抗抑郁药筛选.系列 B 中的化合物对 Sert,Net 和 Dat 的再摄取抑制活性比系列 A 中的更高.系列 B 中哌嗪中心中心和末端苯环之间的间隔物长度似乎发挥了作用.活动中的重要作用.
Doi:10.5012/bkcs.2012.33.8.2597

专利信息

专利号:US-2025129021-A1
优先权日:2023-09-19
标 题:Small molecule protein synthesis modulators
发明人：GYGI DAVID; BAHMANYAR SOGOLE SAMI; HAMANN LAWRENCE
权利人:INTERDICT BIO INC
摘要:The present disclosure provides compounds of the formulae herein (e.g., Formula (I), Formula (V)), and pharmaceutically acceptable salts thereof, which are useful for modulating protein synthesis (e.g., modulating synthesis of BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D). The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts thereof, and methods of treating or preventing diseases or disorders (e.g., diseases or disorders associated with BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D) by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.

专利号:WO-2004087679-A1
优先权日:2003-04-01
标 题 :2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
发明人：OBRECHT DANIEL; ERMERT PHILIPP; LUTHER ANATOL; EBERLE MARTIN; BACHMANN FELIX
权利人:APONETICS AG; OBRECHT DANIEL; ERMERT PHILIPP; LUTHER ANATOL; EBERLE MARTIN; BACHMANN FELIX
摘要:The invention relates to substituted pyrimidines of formula (I) wherein V represents a bond or CR6R7, W represents a bond, NR8 or oxygen, X represents sulfur, or nitrogen substituted by hydrogen or R5, Y represents -CH2-, -CH2CH2-, -CO- or -CS-, R1 represents unsubstituted or substituted aryl or heteroaryl, and the substituents R2, R3, R4, R5, R6, R7 and R8 have the meanings given in the specification. These compounds are selectively inducing apoptosis in cancer cells and can be used for the treatment of neoplastic and autoimmune diseases. The invention relates also to methods of synthesis of such compounds, to their use as medicaments, to pharmaceutical compositions containing same, and to methods of treatment of neoplastic and autoimmune diseases using such compounds of formula (I) or of pharmaceutical compositions containing same.

专利号:US-7989438-B2
优先权日:2007-07-17
标题 :Therapeutic compounds
发明人：CONTE IMMACOLATA; HABERMANN JOERG; MACKAY ANGELA; NARJES FRANK; RICO FERREIRA MARIA DEL ROSARIO; STANSFIELD IAN
权利人:ANGELETTI P IST RICHERCHE BIO
摘要:A class of macrocyclic compounds of formula (I), wherein R 7 , A, Ar, B, D, F, M, Q 1 , Q 2 , W, X, Y and Z are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection.